The authors hypothesized that the emergence of painful bone marrow edema occurs through microembolisms in the bone marrow that may be reflected in elevated plasma parameters of hypofibrinolysis or a disturbance of the lipid metabolism and that treatment with iloprost may lead to a decrease in or normalization of the elevated serum parameters and, therefore, to pain reduction.
T he emergence of bone marrow edema on magnetic resonance imaging (MRI) can be associated with several entities and diseases, and its diagnosis and interpretation have gained interest in recent years. Bone marrow edema has been described in idiopathic, traumatic-induced, degenerative, inflammatory, ischemic, infectious, metabolic/ endocrine, iatrogenic, and neoplastic lesions and in pregnancy. [1] [2] [3] Several hypotheses have been put forth regarding the possible pathogenesis of bone marrow edema, including thromboembolism, obstruction of arteriolar inflow or venous outflow, injury to the vessel wall secondary to vasculitis, altered lipid metabolism, and reduced fibrinolysis. 4 In cases of bone marrow edema syndrome, some authors have postulated that it may be a reversible form or a prestage of osteonecrosis, 5, 6 although histopathological findings did not confirm this theory. 2, 7 Based on the aforementioned theories, laboratory findings of patients with bone marrow edema syndrome or osteonecrosis have demonstrated elevated levels of lipoprotein(a) (Lp[a]), plasminogen activator inhibitor, or apolipoprotein B (ApoB):apolipoprotein A1 (ApoA1) ratios. [8] [9] [10] [11] Numerous studies have reported encouraging results in the treatment of painful bone marrow edema in various regions with iloprost. [12] [13] [14] [15] [16] [17] Iloprost is a prostacyclin analogue that is registered for therapy of critical ischemia secondary to peripheral atherosclerotic obliterative disease, diabetic angiopathy, or pulmonary hypertonus. The substance has a potency to dilate arterioles and venules, reduce capillary permeability, and inhibit thrombocyte aggregation. Apart from the rheologic properties of the terminal vascular bed, it diminishes the concentration of oxygen radicals and leukotrienes. 13 The authors hypothesized that the emergence of painful bone marrow edema occurs through microembolisms in the bone marrow that may be reflected in elevated plasma parameters of hypofibrinolysis or a disturbance of the lipid metabolism and that treatment with iloprost may dilate the embolic bone marrow vessels, restore the local perfusion, and lead to a decrease in or normalization of the elevated serum parameters and hence to pain reduction. This article reports the results of the prospective cohort study conducted to test that hypothesis.
Materials and Methods
Between January 1, 2007, and December 31, 2010, all patients with a painful bone marrow edema ( Figure 1 ) and elevated Lp(a) serum values were regarded as potential candidates for the study. Patients were excluded if they were in the immediate postpartum period; had inflammatory and/or infectious arthritis, tumors, osteoarthritis higher than Kellgren-Lawrence stage II, 18 osteonecrosis higher than Association for Research of Circulation Osseous (ARCO) stage I, 9 or a thrombosis or lung embolism; sustained trauma within 6 months prior to presentation; or took medication that would affect bone turnover. Patients with an atherogenic or thrombophilic risk in their anamnesis were also excluded.
All patients were treated with intravenous iloprost. In clinical use, the most frequent side effects of iloprost are hypotension, headache, nausea, and flush. Contraindications include gravidity, anticoagulative treatment with warfarin or heparin, concomitant gastrointestinal ulcers, heart insufficiency, recent myocardial infarction, or unstable angina pectoris. 13 Patients with these contraindications were excluded.
A total of 21 patients (12 men and 9 women; mean age, 50 years [range, years]) were included in the study. The majority of the cases involved the lower extremities, with the knee joint being the most common localization affected (Table) . The most common cause of bone marrow edema was idiopathic (n59), followed by posttraumatic (n57) ( Table) . All posttraumatic cases had an MRI-diagnosed bone marrow edema that persisted for at least 6 months following injury. No patient had a history of prior painful bone marrow edema or other predisposing factors. At clinical examination, all patients had a positive tapping test over the affected area. 20 Except for 2, all patients had elevated Lp(a) serum concentrations. These 2 patients had repeated unsuccessful conservative treatment prior to admission and reported that iloprost therapy may be their last chance to be pain free.
All patients were treated as inpatients with a series of 5 infusions in an off-label use on 5 consecutive days. Starting with an initial dose of 50 µg of iloprost, the dose was decreased to 25 µg for the second and third days and then to 20 µg for the fourth and fifth days. The dose was decreased during treatment due to the reported side effects of this therapy at high doses. 12 The drug was administered in 500 mL sodium chloride solution over 5 hours using a drop counter. Side effects were documented and symptomatically treated. During iloprost therapy, all patients were allowed to bear weight on the affected extremity as tolerated. No additional pain medication, ultra-low-molecular-weight 
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heparin, or other drugs with a possible effect on the local perfusion were administered.
Informed consent was obtained from all patients prior to therapy.
In all patients, the serum concentrations of Lp(a), ApoA1, and ApoB were determined within 4 weeks before and 6 weeks after iloprost therapy. All plasma values were measured by nephelometry. Normal values for Lp(a), ApoA1, and ApoB are less than 30, 125 to 215, and 55 to 125 mg/dL, respectively. For Lp(a), the lower and upper detection limits of nephelometry are less than 4 and more than 125 mg/dL, respectively.
Following treatment, all patients were evaluated 6 weeks after iloprost therapy clinically and by MRI.
Statistical analysis regarding gender and age was performed by means of the Wilcoxon test. 21 Significance was defined at a P value less than .05.
results
All patients received the iloprost infusions over 5 days. On the first day of iloprost therapy, 12 patients reported headache, 3 reported nausea, and 1 reported flush. After dose reduction on the second day, no further side effects were observed.
At 6-week follow-up, 17 patients reported complete resolution of their symptoms. In these cases, complete bone marrow edema resolution was observed on MRI ( Figure 2 ). Four patients reported that their symptoms were either the same or had worsened, with partial bone marrow edema resolution on MRI. In these patients, Lp(a) values either increased or remained the same (Table) . Three months after iloprost treatment, MRI and laboratory control were performed again. No evidence existed of bone marrow edema in any case. In 1 patient, Lp(a) concentration decreased and the patient had no complaints. In the remaining 3 patients, the symptoms persisted. Further therapy consisted of physical therapy, nonsteroidal anti-inflammatory drugs (NSAIDs), and partial weight bearing of the affected extremity for another 6 weeks, with no positive effect on the clinical outcome. Hence, the total success rate of iloprost therapy was 86% at a mean follow-up of 17 months (range, 3-45 months).
Prior to iloprost therapy, mean ApoA1, ApoB, and Lp(a) values were 159. 8 (Table) .
discussion
The goal of this study was to evaluate serum parameters of hypofibrinolysis and lipid metabolism in patients with painful bone marrow edema and investigate whether treatment with iloprost effected these parameters and the clinical and MRI outcomes. The results demonstrate that iloprost therapy achieves a success rate of 86% in patients with elevated Lp(a) plasma values. At 6-week follow-up, Lp(a) concentrations were significantly decreased. In patients with persistent symptoms, Lp(a) values either increased or remained the same.
Lipoprotein (a) is a low-density lipoprotein (LDL)-like particle in which ApoB-100 is bound with a disulfide bridge to Apo(a). 22 This unique structural feature accounts for the potential atherogenic and thrombophilic activity of Lp(a). 9 In plasma, Lp(a) exists as peaks in the verylow-density lipoprotein (VLDL) rangea form of density intermediate between LDL and high-density lipoprotein (HDL) and another apolipoprotein E-rich fraction closer to the density of HDL. 22 Lipoprotein(a) is made by the VLDL synthesis machinery in the endoplasmic reticulum, and the Apo(a) moiety is added on the surface of hepatocytes. 22 By competing with plasminogen at the fibrin surface for the common lysine binding domains, Lp(a) reduces fibrinolytic activity, causing increased susceptibility to arterial and venous thrombotic events. 10 Plasma concentrations of Lp(a) are correlated inversely with the size of Apo(a) isoproteins. 23 Lipoprotein(a) levels are higher in women than in men, and they do not appear to be affected by physical exercise. 22 Moderate alcohol consumption may lower Lp(a) concentration. 22 Apolipoprotein B, the structural protein for the atherogenic lipoproteins (ie, VLDL; intermediate-density lipoprotein; and both large buoyant LDL and small dense LDL), is responsible for transporting lipid from the liver and gut to the peripheral tissues. 24 Each lipoprotein particle contains 1 ApoB molecule. Plasma ApoB levels increase with aging 25, 26 and are higher in men than in women. 25 Apolipoprotein A1 is the major structural protein for HDL and reflects the atheroprotective side of lipid metabolism. 24 Apolipoprotein A1 is produced in the liver and intestine and is responsible for initiating reverse cholesterol transport, whereby excess cholesterol in peripheral tissues is carried back to the liver for excretion. 24 Apolipoprotein A1 levels are reported to be higher in women than in men. 27 Some studies provide strong evidence for the involvement of hypofibrinolysis in the pathogenesis of avascular necrosis of the hip and in some cases of idiopathic bone marrow edema.
11,28-31 Representing major parameters of hypofibrinolysis, elevated levels of Lp(a), plasminogen activator inhibitor (PAI), or both have been shown to predispose patients to develop these conditions. 9,11 From a pathogenetical standpoint, elevated levels of Lp(a) or PAI favor development of idiopathic bone marrow edema and spontaneous osteonecrosis on the basis of inadequate lysis of intraosseous thrombi and subsequent venous hypertension. 11, 29, 30 Plasminogen activator inhibitor is an important factor in the maintenance of systemic vascular hemostasis. As a major inhibitor of fibrinolysis, elevated levels of PAI are associated with coronary artery stenosis and the recurrence of myocardial infarction or venous thrombosis in young men. 32 Similarly, elevated levels of Lp(a) correlate with the concentration of cardial troponin T in patients with unstable angina 32 and familiarly predispose patients for premature myocardial infarction. 33 In contrast to the extensive laboratory investigations on osteonecrosis, few stud- 
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ies have attempted to interpret laboratory findings at the site of bone marrow edema.
9,10, 35 Berger et al 10 determined various parameters of hypofibrinolysis and thrombophilia in 20 patients with an idiopathic bone marrow edema of the hip, and 20 healthy patients served as a control group. In the bone marrow edema group, elevated levels of Lp(a) and PAI were found in 9 and 2 patients, respectively. Elevation of Lp(a) was present in 2 patients in the control group, whereas PAI values were normal. Mean levels of Lp(a) were significantly higher in the bone marrow edema group compared with the control group, whereas mean concentrations of PAI, apolipoproteins, lipid metabolism parameters, and indicators of thrombophilia did not differ between groups. 10 Lakhanpal et al 35 described elevated levels of serum alkaline phosphatase in only 1 of 56 patients with idiopathic bone marrow edema.
Several operative and conservative treatments have been described in the management of painful bone marrow edema and bone marrow edema syndrome. Treatment with protected weight bearing, NSAIDs, and physical therapy reduces pain, preserves mobility, and prevents contractures. 36 In cases of bone marrow edema syndrome, core decompression has been recommended for rapid and complete reduction of symptoms and return to normal MRI signal patterns. 37 This method is based on the theory that pain in bone marrow edema syndrome and avascular necrosis is caused by elevated intramedullary pressure. Although this treatment has a low rate of complications, 6 weeks of partial or complete weight bearing is recommended, followed by physical therapy. Lakhanpal et al 35 reported no beneficial effect using calcitonin, antituberculous drugs, prednisone, and lumbar sympathectomy. Boos et al 38 reported good clinical results with sympathetic nerve blockade in 3 patients but no improvement in pathologic MRI signal patterns.
In past years, the use of biphosphonates has also demonstrated good results in the treatment of bone marrow edema syndrome. 39, 40 However, biphosphonates should be used with caution. 41 Biphosphonates, such as alendronate, have a long half-life (approximately 10 years). Due to the long persistence in bone and release of alendronate from bone, it is possible that alendronate is released into the bloodstream long after the cessation of treatment. In cases of pregnant women, this may have a negative effect on the fetus because alendronate can pass through the placenta and accumulate in the fetus.
Intravenous iloprost in the treatment of bone marrow edema syndrome was initially introduced by Aigner et al. 12, 13, 42, 43 Their experience with iloprost in large patient groups has shown excellent results in the treatment of bone marrow edema syndrome of the hip and knee joint 15 and the talus. 12 Patients were pain free within the first days of therapy, and MRI changes resolved completely after 6 to 12 weeks of treatment. Iloprost therapy accelerated the resolution process of pathologic MRI changes compared with the normal period of spontaneous remission, which is 6 to 12 months. In an MRIcontrolled study, they demonstrated that the parenteral application of iloprost can achieve equal or better results in the treatment of bone marrow edema syndrome of the hip compared with core decompression. 43 Similarly, Arazi et al 14 reported good results after treatment of a bone marrow edema after ankle arthroscopy by iloprost infusions. Tillmann et al 16 introduced iloprost therapy in the treatment of posttransplant distal limb syndrome with successful results. Generally, the success of different treatment options is highly dependent on the stage of the disease; best results are seen in cases of bone marrow edema alone, with poorer prognoses for bone marrow edema with advanced bone necrosis or osteoarthritis.
To the authors' knowledge, the current study is the first to show that elevated Lp(a) values may indicate a reversible stage of bone marrow edema that could be successfully treated with intravenous iloprost in 86% of cases. In patients with persisting symptoms, the Lp(a) serum concentrations increase or remain the same despite uneventful MRI findings. This may be a case in which MRI has a diagnostic window regarding osseous microprocesses and microcirculation, which may lead to bone marrow edema emergence. A diagnostic window of MRI has been described at the site of osteonecrosis and may extend between 6 weeks. 44 Moreover, the significant decrease of all determined plasma parameters is supportive of the theory that hypofibrinolysis or disturbances in the lipid metabolism may play a crucial role in bone marrow edema emergence. Although ApoA1 and ApoB concentrations were within normal values prior to iloprost therapy, the significant decrease following treatment indicates this possible role.
In the current study, a high rate of side effects was observed on the first day of therapy, which can be attributed to the high initial dose of the drug and its vasodilatative effect. Nevertheless, a high initial dose is an indispensable premise for osseous vasodilatation. Therefore, the authors do not recommend lowering the initial dose. However, patients should be informed about these possible side effects prior to the start of treatment.
A limitation of this study is the lack of a control group with normal Lp(a) plasma values. Based on the findings of this study, the authors plan to conduct such a comparative study. Should the current observations be confirmed in future studies, this would support even more the potential role of hypofibrinolysis or disturbances in lipid metabolism in the emergence of painful bone marrow edema. Moreover, all serum values were determined only once, rendering the detection of changes in concentrations after bone marrow edema remission unfeasible. Furthermore, the atherogenic and thrombophilic profile of the patients was assessed based solely on the anamnesis. Therefore, uncertainty remains as to whether higher ApoA1 or ApoB values can be attributed exclusively to the bone marrow edema pathogenesis. The exact duration of bone marrow edema in each case was unknown, which may also influence the plasma levels of ApoA1, ApoB, or Lp(a). However, strict exclusion criteria were used to rule out systemic or local factors that would have altered the results. The high statistical significance of the results supports the authors' hypothesis regarding the emergence of bone marrow edema.
conclusion
This study demonstrates that elevated Lp(a) serum values may be indicative of a reversible, painful bone marrow edema. Moreover, they may act as a diagnostic tool and are a good predictor for successful outcome after iloprost therapy.
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